ConTiPi Medical Overview
ConTIPI Medical develops noninvasive and disposable vaginal devices for women with pelvic floor disorders such as stress urinary incontinence and pelvic organ prolapse. The company's devices are inserted vaginally using a disposable applicator, then open to provide support to predefined vaginal walls. For removal and disposal, a pull of the attached string collapses the device into its original size. One of the company's first devices, for the management of stress urinary incontinence in women, was sold to Kimberly Clark Worldwide Inc. and is now marketed in North America under the name Poise Impressa. ConTIPI Medical also offers ProVate, a ring pessary solution designed for pelvic organ prolapse. The device is inserted by the user in its small form, then enlarges into a ring of up to 91 millimeters. After up to seven days of use, a pull of the string collapses the ring back into its tiny dimensions for removal and disposal. ProVate has a 510(k) clearance from FDA for marketing in the United States, and a CE Mark for marketing in the EU. The ProVate Device is ready for the market, and ConTIPI Medical hired Bourne Partners (Charlotte, NC, United States) as its mergers and acquisitions advisor.
Cumulative Funding Raised Over Time ($)
$40.0MJun 2023
$51.0MNov 2018
Latest News
growth-positive
ConTIPI Medical Ltd Raises $40MM of Structured Capital from Capital IP Investment Partners and Ghost Tree Partners
ConTIPI Medical Ltd, an Israeli medical device company, has raised $40MM of structured capital from Capital IP Investment Partners and Ghost Tree Partners. The funds will be used to bring ConTIPI’s new product, ProVate, to the market. ProVate is a non-surgical and disposable solution for women suffering from Pelvic Organ Prolapse (POP). The company also announced a commercial partnership with Indegene, a digital-first, life science commercialization company, which will provide several services across the commercialization process.
InvestmentPartners
growth-positive
Indegene and ConTIPI expand partnership to commercialise ProVate device
Indegene plans to expand its partnership with ConTIPI Medical to bring the ProVate device to assist women experiencing pelvic organ prolapse (POP). The ProVate device is a ready-to-use device designed for vaginal insertion. ConTIPI has already received regulatory clearances for the device. The expanded partnership will involve various services throughout the commercialization process, including pricing, reimbursement, market access, pharmacovigilance, medical communications, sales, regulatory, marketing, and commercial operations support. Indegene will provide data-driven omnichannel marketing solutions to enhance revenue and ensure a predictable cash outflow for ConTIPI. The partnership aims to offer ConTIPI strategic advantage and trusted services.
Partners
growth-positive
Indegene and ConTIPI Medical Ltd partner to bring innovative disposable non-surgical device to market to help women suffering from Pelvic Organ Prolapse (POP)
Indegene and ConTIPI Medical have announced a partnership to bring a new device to the market to help women suffering from Pelvic Organ Prolapse (POP). The device, called ProVate, is a ready-to-use device that is inserted vaginally by the user herself. It provides support to specific sites along the vaginal walls and can be easily removed and disposed of. Indegene will be supporting ConTIPI in educating healthcare providers and affected women on the devices benefits and assisting with the devices launch in the market. The partnership aims to empower women to take control of their healthcare and provide them with the freedom to choose how and when to manage this medical problem.
Partners
growth-positive
A New Self-use Innovative Treatment for Pelvic Organ Prolapse in Women (POP) Designed by ConTIPI Medical
ConTIPI Medical, a company that develops non-surgical and disposable vaginal solutions for women with Pelvic Floor Disorders, has developed the ProVate Device for the management of Pelvic Organ Prolapse (POP). The device is designed to overcome the downsides of existing pessaries, offering a disposable and small-sized solution that puts control in the hands of the patient. A marketing survey conducted by Frost & Sullivan showed high interest and positivity among patients and physicians for the ProVate device, with potential for high economic value. The survey revealed that current treatment options for POP, including surgery and pessaries, are not satisfactory due to complications and side effects. The ProVate device offers a non-surgical, non-invasive, and lower-risk alternative for POP management.
Customers
growth-positive
Dr. Elan Ziv in Brussels to present revolutionary device that improves quality of life for millions of women - Brussels Express
ConTIPI, a FemTech company, has developed a disposable vaginal device to help women suffering from pelvic organ prolapse (POP). The device, which can be inserted at home, stays in the body for up to seven days, reducing discomfort and giving women more control. The companys CEO, Dr. Elan Ziv, revealed that the product has received clearance from the Food and Drug Administration for marketing in the US and the CE marking in Europe. ConTIPI is open to partnerships to help bring the product to market. The companys first device, designed for stress urinary incontinence, was acquired by Kimberly Clark Worldwide.
CustomersPartnersExpand
| Sector | Health Tech & Life Sciences |
Funding
| Total funding | $11M |
| Last funding | $40M |
| Stage | A |
| Rounds | 2 |
| Investors | 5 |
Team Members
3
Employees: 1-10
Web & Social Links
| Website | contipi.com |
Locations
Alon ha-Tavor St 2, Caesarea, Israel
Photos & Videos
4 item(s)
ConTiPi Medical Business
Business models
B2C, B2B
Product stage
Released
Employees
1-10
Sector
Health Tech & Life SciencesMedical DevicesMedical Treatment & TherapeuticsTarget Customer
Healthcare & Life SciencesHealthcareProvidersConsumersDemographics & FamilyWomenCore Technology
—Tags (7)
femtechmedical-devicesgynecologywomenwomen-healthhome-carenon-invasiveGeographic Markets
AmericasEuropeConTiPi Medical Financials
$11M
Total funding
Undisclosed
Capital raised
$40M
Last funding
A
Funding stage
2
Total rounds
5
Investors
Cumulative Funding Raised Over Time ($)
$40.0MJun 2023
$51.0MNov 2018
Private Equity Funding
Debt Financing
Jun 2023
$40M
Capital Point
A Round
Nov 2018
$11M
Zeev Bronfeld, Boris Krasny, Capital Point, Elan Ziv, Neo Pharm
ConTiPi Medical Lifecycle
Cumulative Funding Raised Over Time
$40.0MJun 2023
$51.0MNov 2018
All Events
Debt Financing
Jun 2023
$40M
Capital Point
A Round
Nov 2018
$11M
Zeev Bronfeld, Boris Krasny, Capital Point, Elan Ziv, Neo Pharm
ConTiPi Medical News
10 articles
growth-positive
ConTIPI Medical Ltd Raises $40MM of Structured Capital from Capital IP Investment Partners and Ghost Tree Partners
ConTIPI Medical Ltd, an Israeli medical device company, has raised $40MM of structured capital from Capital IP Investment Partners and Ghost Tree Partners. The funds will be used to bring ConTIPI’s new product, ProVate, to the market. ProVate is a non-surgical and disposable solution for women suffering from Pelvic Organ Prolapse (POP). The company also announced a commercial partnership with Indegene, a digital-first, life science commercialization company, which will provide several services across the commercialization process.
InvestmentPartners
growth-positive
Indegene and ConTIPI expand partnership to commercialise ProVate device
Indegene plans to expand its partnership with ConTIPI Medical to bring the ProVate device to assist women experiencing pelvic organ prolapse (POP). The ProVate device is a ready-to-use device designed for vaginal insertion. ConTIPI has already received regulatory clearances for the device. The expanded partnership will involve various services throughout the commercialization process, including pricing, reimbursement, market access, pharmacovigilance, medical communications, sales, regulatory, marketing, and commercial operations support. Indegene will provide data-driven omnichannel marketing solutions to enhance revenue and ensure a predictable cash outflow for ConTIPI. The partnership aims to offer ConTIPI strategic advantage and trusted services.
Partners
growth-positive
Indegene and ConTIPI Medical Ltd partner to bring innovative disposable non-surgical device to market to help women suffering from Pelvic Organ Prolapse (POP)
Indegene and ConTIPI Medical have announced a partnership to bring a new device to the market to help women suffering from Pelvic Organ Prolapse (POP). The device, called ProVate, is a ready-to-use device that is inserted vaginally by the user herself. It provides support to specific sites along the vaginal walls and can be easily removed and disposed of. Indegene will be supporting ConTIPI in educating healthcare providers and affected women on the devices benefits and assisting with the devices launch in the market. The partnership aims to empower women to take control of their healthcare and provide them with the freedom to choose how and when to manage this medical problem.
Partners
growth-positive
A New Self-use Innovative Treatment for Pelvic Organ Prolapse in Women (POP) Designed by ConTIPI Medical
ConTIPI Medical, a company that develops non-surgical and disposable vaginal solutions for women with Pelvic Floor Disorders, has developed the ProVate Device for the management of Pelvic Organ Prolapse (POP). The device is designed to overcome the downsides of existing pessaries, offering a disposable and small-sized solution that puts control in the hands of the patient. A marketing survey conducted by Frost & Sullivan showed high interest and positivity among patients and physicians for the ProVate device, with potential for high economic value. The survey revealed that current treatment options for POP, including surgery and pessaries, are not satisfactory due to complications and side effects. The ProVate device offers a non-surgical, non-invasive, and lower-risk alternative for POP management.
Customers
growth-positive
Dr. Elan Ziv in Brussels to present revolutionary device that improves quality of life for millions of women - Brussels Express
ConTIPI, a FemTech company, has developed a disposable vaginal device to help women suffering from pelvic organ prolapse (POP). The device, which can be inserted at home, stays in the body for up to seven days, reducing discomfort and giving women more control. The companys CEO, Dr. Elan Ziv, revealed that the product has received clearance from the Food and Drug Administration for marketing in the US and the CE marking in Europe. ConTIPI is open to partnerships to help bring the product to market. The companys first device, designed for stress urinary incontinence, was acquired by Kimberly Clark Worldwide.
CustomersPartnersExpand
growth-positive
FemTech - Making strides for women
The article discusses the growing focus on FemTech, technology aimed at womens health, particularly in relation to pelvic floor dysfunctions. It highlights the work of Dr Elan Ziv, who has developed non-surgical, disposable devices to manage these conditions. The first device, for stress urinary incontinence, has been acquired by an American company and is available in North America. A second device for pelvic organ prolapse has received clearance for the European and American markets. The article suggests that the adoption of the Health Technology Assessment proposal could boost innovation in womens health, a sector predicted to be worth over $50 billion by 2025.
AcquisitionExpand
growth-positive
ConTIPI Medical Has Received FDA Approval for the Marketing of a Unique Product for the Treatment of Pelvic Organ Prolapse in Women
ConTIPI Medical Ltd. has received FDA approval to market its new product designed to treat pelvic prolapse in women. The Israeli biotechnology company, founded in 2014, develops disposable and non-invasive devices for the treatment of pelvic floor dysfunctions. The approval is a major breakthrough in a market that has lacked significant clinical innovations in the last 20 years. The companys products empower women to control their medical condition discreetly and conveniently. With an estimated market size of $20 billion a year, the company is expected to experience positive growth in the coming years. ConTIPI Medical Ltd. has received investments totaling over $13 million to date.
Customers
growth-positive
Pelvic disorder co ConTIPI Medical raises $11m
ConTIPI Medical, a company that has developed non-surgical and disposable vaginal solutions for women with Pelvic Floor Disorders, has completed a $3 million financing round, bringing the total amount raised for its new product to $11 million. The round included both new and previous investors. The company aims to compete the development of its product line. The product has already been approved for marketing in Europe and is undergoing clinical trials for FDA approval in the US.
Investment
growth-positive
ConTIPI Medical Launches a New Website Highlighting Nonsurgical Devices for Pelvic Floor Disorders
Israeli medical device company ConTIPI Medical provides non-surgical and disposable vaginal solutions for women with Pelvic Floor Disorders. Their products, the Impressa Device and the ProVate Device, offer non-invasive management for Stress Urinary Incontinence and Pelvic Organ Prolapse respectively. The devices are designed to be user-friendly and can be used in the comfort of ones home. ConTIPI Medical is led by a strong management team and is currently launching a new website.
Customers
growth-positive
ConTIPI Medical develops tampon-like medical devices
ConTIPI Medical, a medical device company, has revealed its history and future plans. The company developed a tampon-like product for the treatment of incontinence and obtained FDA approval. They signed a marketing agreement with Procter and Gamble, but the agreement was terminated when Procter and Gamble sold their prescription products business. ConTIPI then partnered with Kimberly Clark and sold the company for $90 million. The product is currently sold in the US market. ConTIPI Medical is now focused on developing a product for pelvic organ prolapse (POP) and is raising $10-12 million in funding. The company plans to market the product through a medical equipment company.
PartnersInvestment
ConTiPi Medical Team
Employee Info
| Employees (range) | 1-10 |
| Exact count | 4 |
| Team members | 3 |
Similar Companies
Similar companies data is computed dynamically and not stored in the entity profile. This section requires implementing a similarity query (e.g. by classification overlap, sector, district).
This entity has 9 classification IDs that could be used for matching.
ConTiPi Medical Internal
Recent Updates
No update log entries.
Note: Free-text notes visible in the original Finder "Internal" tab are not present in the imported profile data. Only the update audit log is available.
Admin Info
| Confidence | 100/100 |
| Missing | markets |
| BI Verification | Jenny Sotnik-Talisman |
| Registrar ID | 515020899 |
| Crunchbase | contipi-medical |
| Phone | +97246276066 |
| Creator | Paz Eliav |
| Creator email | paze@cet.ac.il |
| Last updater | Yanina Wainscheinker |
| Updater email | yanina.wainscheinker@sncentral.org |
| Last update | 2023-06-28T00:00:00.000Z |
| Created | 2015-02-15T00:00:00.000Z |
| Claimed | Yes |